ID   NT-18LM
AC   CVCL_C4N5
DR   Wikidata; Q116050014
RX   PubMed=36269546;
CC   Doubling time: 6.35 days (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:2681; DAXX; Simple; p.Cys629Leufs*29 (c.1884dupC); Zygosity=Unspecified (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Arg29Ter (c.85C>T); ClinVar=VCV000200970; Zygosity=Unspecified (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:11633; TCF3; Simple; p.Lys101Arg (c.302A>G); ClinVar=VCV000810990; Zygosity=Unspecified (PubMed=36269546).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C172814; Pancreatic neuroendocrine tumor G3
DI   ORDO; Orphanet_97253; Neuroendocrine tumor of pancreas
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C4N6 ! NT-18P
OI   CVCL_C4N7 ! NT-36
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 4
//
RX   PubMed=36269546; DOI=10.1007/s13402-022-00727-z; PMCID=PMC9747820;
RA   Viol F., Sipos B., Fahl M., Clauditz T.S., Amin T., Kriegs M.,
RA   Nieser M., Izbicki J.R., Huber S., Lohse A.W., Schrader J.;
RT   "Novel preclinical gastroenteropancreatic neuroendocrine neoplasia
RT   models demonstrate the feasibility of mutation-based targeted
RT   therapy.";
RL   Cell. Oncol. (Dordr.) 45:1401-1419(2022).
//